Momenta Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA Inc, No. 14-1274 (Fed. Cir. Nov. 10, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs-appellants Momenta Pharmaceuticals, Inc. and Sandoz Inc. (collectively, “Momenta”) appeal the district court’s decision finding Teva Pharmaceuticals USA Inc. (“Teva”) does not infringe U.S. Patent No. 7,575,886 (“ the ’886 patent”). In a companion case, Mo- menta appeals the district court’s decision finding A m- phastar Pharmaceuticals, Inc., International Medication Systems, Ltd., Actavis, Inc., and Actavis Pharma, Inc. (collectively, “Amphastar”) do not infringe the ’886 patent.